Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CCR5 | P51681 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459461 | 0.94 | KMT2A (0.63) | KMT2AHTTMAPTL3MBTL1TSHR | |
| SCHEMBL4212339 | 0.81 | TP53 (0.67) | KMT2AMAPTL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1563603 | 0.81 | L3MBTL1 (0.53) | KMT2AHTTMAPTL3MBTL1CCR5 | |
| SCHEMBL4206740 | 0.79 | PKM (0.67) | KMT2AHTTMAPTL3MBTL1TSHR | |
| SCHEMBL4198177 | 0.77 | TSHR (0.68) | KMT2AHTTMAPTL3MBTL1TSHR | |
| SCHEMBL12459467 | 0.77 | LMNA (0.69) | KMT2AHTTMAPTTSHRALDH1A1 | |
| SCHEMBL1563274 | 0.75 | KMT2A (0.53) | KMT2AHTTCCR5ALDH1A1RECQL | |
| SCHEMBL12459463 | 0.74 | CYP3A4 (0.67) | KMT2AHTTL3MBTL1ALDH1A1PTGES | |
| SCHEMBL1563417 | 0.73 | KMT2A (0.54) | KMT2AHTTMAPTL3MBTL1TSHR | |
| SCHEMBL13905646 | 0.73 | TSHR (0.67) | KMT2AMAPTL3MBTL1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2353593-B1 | Non-nucleoside reverse transcriptase inhibitors | ARDEA BIOSCIENCES INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2353593-A1 | Non-nucleoside reverse transcriptase inhibitors | Ardea Biosciences, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-1545483-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1545483-A4 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20060135556-A1 | Non-nucleoside reverse transcriptase inhibitors | INTRABIOTICS PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1545483-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Ribapharm Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004030611-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RIBAPHARM INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, TYMP, RNGTT | KMT2A 911/4885HTT 2326/4885MAPT 702/4885 |
| US-20060135556-A1 | Non-nucleoside reverse transcriptase inhibitors | POLRMT, TYMP, RNGTT | KMT2A 911/4885HTT 2326/4885MAPT 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.